**Case Report**

**Leukoerythroblastosis as an Unusual Presentation of Parvovirus B19 Infection in a Sickle Cell Patient**

Pratik A. Patel, Elizabeth P. Weinzierl, and Daniel S. Wechsler

1Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA, USA
2Department of Pathology, Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA
3Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

Correspondence should be addressed to Daniel S. Wechsler; dan.wechsler@emory.edu

Received 16 April 2020; Revised 9 September 2020; Accepted 10 September 2020; Published 22 September 2020

Academic Editor: Marie Louise von Linstow

Copyright © 2020 Pratik A. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parvovirus B19 infection in pediatrics most commonly causes fifth disease, a mild viral illness. Hematologic manifestations include severe anemia, especially in patients with chronic hemolytic anemias or who are immunocompromised. Because of the shortened life span of erythrocytes in patients with sickle cell disease, parvovirus infection can cause transient aplastic crisis which can be life-threatening. However, leukocytosis and thrombocytosis are rarely seen. We report leukoerythroblastosis as an unusual presentation of acute parvovirus B19 infection in a previously splenectomized 12-year-old boy with sickle cell disease.

1. Introduction

Parvovirus B19 infection is frequently diagnosed in the pediatric population and can be severe in patients with chronic hemolytic anemias such as sickle cell disease. Patients typically present with severe anemia and/or pancytopenia. Here, we describe an unusual presentation of acute parvovirus B19 infection in a patient with sickle cell disease.

2. Case Presentation

A 12-year-old boy with sickle cell disease (HbSS) with a history of splenectomy presented to the emergency room for fatigue, headaches, and near syncope. On examination, the patient was tachycardic with a grade 3/6 systolic ejection murmur, marked pallor, and shotty cervical and inguinal lymphadenopathy.

Complete blood count (CBC) showed a white blood cell (WBC) count of $72.2 \times 10^9/L$ (65.4% neutrophils, 10.3% band forms, 2.7% metamyelocytes, 0.3% myelocytes, 12.3% lymphocytes, 6.7% monocytes, 0.3% eosinophils, and 2% blasts), hemoglobin 3.9 g/dL (baseline hemoglobin 9 g/dL), platelets (PLT) $1533 \times 10^9/L$, and 15.3 nucleated red blood cells (RBCs) per 100 WBCs. The reticulocyte count was 1.2%. Morphologic examination of the peripheral blood showed a marked leukoerythroblastosis, rare myeloblasts (~1%), markedly abundant nucleated RBCs, and thrombocytosis with many large and giant platelets (Figure 1). Lactate dehydrogenase was 772 U/L (normal 157–272 U/L), and uric acid was 5.6 mg/dL (normal 2.6–6.8 mg/dL). Coagulation studies were within normal limits. Of note, ten days earlier, the patient was evaluated at an outside hospital for fever and had a normal CBC: WBC of $12 \times 10^9/L$, hemoglobin 9.2 g/dL, and PLT $550 \times 10^9/L$.

Based on the presenting CBC, there was concern for a myeloproliferative neoplasm (MPN) such as chronic myeloid leukemia (CML). Peripheral blood flow cytometry showed a myeloid left shift but no abnormal hematolymphoid cell population. Fluorescence in situ hybridization (FISH) testing for the BCR-ABL1 translocation was negative. CMV and EBV were undetectable by PCR. Because of the severe sudden drop in hemoglobin combined with reticulocytopenia, parvovirus studies were also sent. Parvovirus B19 IgM was positive, and IgG was negative; the parvovirus B19 PCR titer was $6.6 \times 10^7 IU/ml$ (negative <199 IU/ml) with 1 IU equal to 0.79 copies of parvovirus B19. The patient was transfused with packed red blood cells and received intravenous hydration. Within 48 hours, his
WBC count had fallen to \(20.7 \times 10^9/L\) and he was discharged with close outpatient follow-up. Six days later in clinic, his WBC had normalized to \(9.35 \times 10^9/L\) and his PLT count was \(1143 \times 10^9/L\).

### 3. Discussion

This child with sickle cell disease presented with blood counts concerning for a MPN but was ultimately diagnosed with transient leukoerythroblastosis in the setting of acute parvovirus B19 infection. The diagnosis of acute parvovirus B19 is typically made with serology being positive for IgM and negative for IgG and parvovirus B19 DNA PCR positive \([1–3]\). While parvovirus B19 viral DNA can be detectable for many months, the titer is usually highest during the acute presentation \([4]\). Parvovirus B19 infection can span from asymptomatic to life-threatening, depending on the status of the infected host. Patients with sickle cell disease and other chronic hemolytic anemias often develop transient aplastic crisis as a result of acute parvovirus B19 infection \([5, 6]\), which primarily affects erythroid progenitor cells. Other common hematologic manifestations of acute infection in this patient population include reticulocytopenia and leukopenia \([1]\). Similarly, immunocompromised patients (e.g., those undergoing treatment of leukemia) with parvovirus infection may develop cytopenias as well \([7]\). Other causes of severe anemia in patients with sickle cell disease include splenic sequestration, acute chest syndrome, hyperhemolysis, and sepsis \([8, 9]\). Along with severe anemia, parvovirus infection in patients with sickle cell disease classically presents with reticulocytopenia which was seen in this patient. However, the patient also had marked leukocytosis and thrombocytosis, unusual in the setting of parvovirus infection \([1, 10, 11]\). Leukocytosis \(>50 \times 10^9/L\) can be an indication of hematologic malignancy, but is not always associated with a diagnosis of leukemia \([12]\).

Leukoerythroblastosis is a rare condition which is characterized by leukocytosis and the presence of erythroid precursors and myeloid blasts in the peripheral blood. Five cases of parvovirus B19-associated leukoerythroblastosis have been reported \([13–17]\), but all of these patients were neonates and infants (age range preterm neonates to 11 months) and none had thrombocytosis (range \(63–250\times 10^9/L\)); in addition, none of them had sickle cell disease. The 12-year-old sickle cell patient described here had an unusual presentation of leukoerythroblastosis in conjunction with transient aplastic crisis secondary to parvovirus B19 infection. The profound thrombocytosis was likely due to a hyperactive marrow, given the degree of anemia on presentation. Patients with splenectomies also tend to have higher platelet counts, including those with chronic hemolytic anemias such as sickle cell disease and hyposplenism \([18]\). Although Jen and Jackups noted similar findings in a 3-year-old patient with sickle cell disease \([19]\), our patient is the oldest reported patient with leukoerythroblastic reaction in response to parvovirus B19 infection. Disorders such as myelodysplastic syndrome and CML have been temporally associated with concurrent viral infections such as EBV and parvovirus B19 \([20–23]\). Our patient’s presentation suggests that viral serologies and parvovirus B19 DNA PCR should be considered in the workup of older children who present with leukoerythroblastosis.

### Disclosure

This work was performed as part of the authors’ employment by Children’s Healthcare of Atlanta, Atlanta, GA.

### Conflicts of Interest

The authors have no conflicts of interest to disclose relevant to this article.

### References


